| Developers: | Biocad |
| Branches: | Pharmaceutics, medicine, health care |
Herticad (Trastuzumab) - a domestic bioanalogue of medicine trastuzumab, a monoclonal antibody. It is applied in therapy of a breast cancer and cancer of a stomach with HER2 hyper expression.
2020: Obtaining the registration certificate in Bosnia and Herzegovina
On March 30, 2020 Biocad reported that two of its medicines, Acellbia (MNN: rituximab) and Herticad (MNN: trastuzumab), received the first European registration certificate in Bosnia and Herzegovina. Registration is received with assistance of the partner of ICM d.o.o and 5 years work. The first deliveries are going to start in June, 2020. Read more here.
.jpg)
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |